November 20, 2013
Launch of Sancuso in Taiwan
Taipei, Taiwan, November 20, 2013 --- Kyowa Hakko Kirin Taiwan Co., Ltd., (General Manager: Yu, Kuo Jung; "Kyowa Hakko Kirin Taiwan") announced today that Sancuso transdermal patch 3.1 mg/24hours (nonproprietary name: Granisetron; referred to below as "Sancuso") had launched on November 18, 2013 in Taiwan. This product is sublicensed from Solasia Pharma K.K. and Solasia Pharma K.K is licensed from ProStrakan Group plc*.
Sancuso is a transdermal patch placed on the outside part of the upper arm that provides continuous control of nausea and vomiting through transdermal delivery. It is the first and only treatment for nausea and vomiting in people receiving some types of chemotherapy treatment, which does not require pills or an injection.
Product summary for Sancuso
|Brand name||Sancuso transdermal patch 3.1 mg/24hours|
|Indications||Sancuso is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.|
|Dosage and administration||The transdermal system (patch) should be applied to clean, dry, intact healthy skin on the upper outer arm. Sancuso should not be placed on skin that is red, irritated and damaged.
Each patch is packed in a pouch and should be applied directly after the pouch has been opened.
The patch should not be cut into pieces.
Sancuso is a registered trademark of Solasia Pharma K.K..
* ProStrakan Group plc is a subsidiary of Kyowa Hakko Kirin Co., Ltd.
Kyowa Hakko Kirin